Pilot Study: PARP1 Imaging in Advanced Prostate Cancer

PURPOSE: PARP inhibitor (PARPi) therapy is approved for patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) genomic aberrations. However, only a fraction of patients with BRCA1/2 mutations respond to PARPi therapy. In this pilot study, we a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dehdashti, Farrokh, Reimers, Melissa A., Shoghi, Kooresh I., Chen, Delphine L., Luo, Jingqin, Rogers, Buck, Pachynski, Russell K., Sreekumar, Sreeja, Weimholt, Cody, Zhou, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Brief Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681698/
https://www.ncbi.nlm.nih.gov/pubmed/35701722
http://dx.doi.org/10.1007/s11307-022-01746-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681698/
https://www.ncbi.nlm.nih.gov/pubmed/35701722
http://dx.doi.org/10.1007/s11307-022-01746-w

Ejemplares similares